Alpinetin Alleviates Cardiac Inflammation and Remodeling via TLR4/MyD88/NF-κB Signaling Pathway in Rats with Acute Myocardial Infarction.
- 2025-10-16
- International journal of molecular sciences 26(20)
- Mei Feng
- Xinxiang Chen
- Fan Huang
- Lin Chen
- Can Liu
- Wei Li
- Yinyan Li
- Shaobin Chen
- Zhen Deng
- Zhengyi Wei
- Yuan Luo
- Xiyong Yu
- Aiping Qin
- PubMed: 41155364
- DOI: 10.3390/ijms262010073
Study Design
- Population
- rats with acute myocardial infarction (AMI)
- Methods
- Systematic investigation in a rat AMI model, comparing alpinetin to other flavonoids
- Funding
- Unclear
- Rigorous Journal
- Animal Study
Alpinetin, a distinctive plant-derived dihydroflavonoid from cardamom seeds, represents an under-explored chemical scaffold compared to common flavonoids like quercetin or kaempferol. While many flavonoids have shown general cardioprotective potential, the structural specificity of alpinetin may confer unique pharmacological advantages. Inspired by its historical use in traditional Chinese medicine for cardiac discomfort, this study systematically investigated its efficacy against acute myocardial infarction (AMI). In a rat AMI model, alpinetin demonstrated superior infarct size reduction and functional recovery relative to other tested flavonoids. It significantly attenuated key AMI pathologies-including inflammatory infiltration, CD68+ macrophage activation, IL-6/TNF-α release, collagen deposition, and cardiomyocyte apoptosis-more effectively than common flavonoid benchmarks. Mechanistically, alpinetin selectively targeted the TLR4/MyD88/NF-κB signaling axis with notable potency, a pathway not robustly modulated by other flavonoids in the screening. These findings not only validate the traditional wisdom of cardamom but also establish alpinetin as a structurally and mechanistically distinct flavonoid with high translational promise, offering a new candidate for the targeted treatment of ischemic heart disease.